Executive Summary / Investment Rational Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.

A Clinical Stage Radiopharmaceutical Company Developing Novel Peptide-Based Radioligand Therapies (RLTs) For Cancer. Nuclear Oncology, a Clinically Validated Biotech Sector, With Multiple M&As and Platform Deals ($10B+ 1year). Raised $20M+ for Novel RLT Pipeline Utilizing Proprietary Peptide-based Radioligand Platform – Backbone Dynamics. Lead Program, DOTA-PTR-58, First-In-Class SSTR3+ RLT Demonstrated Safety And Tumor Uptake In FIH. Leadership Strength In Peptide Drugs.

Clinical stage radiopharmaceutical company developing novel Peptide-based Radioligand Therapies (RLT) for cancer. Clinically validated sector, multiple recent M&A and platform deals. ($10B+ in 12month). Company raised $20M+ to develop novel pipeline utilizing proprietary peptide Radioligand Platform – Backbone Dynamics. Lead Program, DOTA-PTR-58, First-In-Class SSTR3+ RLT demonstrated safety and tumor uptake In FIH, Phase 1b planned H12025. Management strength in peptide drugs.

o Core Technology What is the technology, its uniqueness, and its value proposition?

Core technology is a proprietary peptide Backbone-Dynamics platform utilizing cyclic backbone and in-silico AI to rapidly design highly specific ligands which bolster our team's pioneering work in peptide backbone cyclization. This differentiated platform facilitates the rapid discovery of promising radioligands. Backbone Dynamics introduces conformational constraint into flexible peptides to significantly enhance stability, affinity & selectivity and boosts their radiotherapeutic profile.

o Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

Broad pipeline of novel RLTs, clinically validated tumor targets and Isotopes. Lead program, DOTA-PTR-58 Theranostic, novel first-in-class SSTR3 RLT targeting Sarcoma, Melanoma, HCC and NET, demonstrated First-In-Human (FIH) safety and tumor uptake, preIND submitted, Phase 1b planned H12025. Additional novel RLT programs in lead-generation and lead optimization stages, 2nd program milestone IND in 2025. Strong NCE (New Chemical Entity) IP.

o Business Strategy Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.

Recently approved RLTs Lutathera (SSTR2+ GEP-NET) and Pluvicto (PSMA+ prostate cancer) gained commercial success and have spurred multi-billion-dollar deals including 4-M&A, 4-Platform Collaboration and 1-licensing deals. The company strategy is to advance novel RLTs to early clinical development and license programs and is also planning to advance platform collaboration discovery deals with major pharma companies by 2025.

o What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans
The company is well-positioned to take advantage of the market interest in novel RLTs through potential financing and M&A opportunities as we further advance pipeline and platform technology. The company is planning a capital raise round to fund the lead program Phase 1b clinical trial and to advance the pipeline and bolster the platform technology to enable platform collaboration deals,